Slapak C A, Daniel J C, Levy S B
Department of Medicine, New England Medical Center, Boston, Massachusetts.
Cancer Res. 1990 Dec 15;50(24):7895-901.
First-step Adriamycin (doxorubicin)-resistant mutants of the murine erythroleukemia cell line PC4 were cloned from Adriamycin-containing (10 ng/ml) methylcellulose at a frequency of 3 x 10(-4). They demonstrated 1.6- to 2.4-fold stable resistance to Adriamycin. Most were cross-resistant to etoposide, but not to vincristine, and were without enhanced expression of mdr genes, which code for P-glycoproteins. Two different murine erythroleukemia cell lines, PC4 and C7D, were passaged in suspension culture into stepwise increasing amounts of Adriamycin. No high-level resistant mutants were isolated de novo; cells initially displayed low-level resistance to Adriamycin and etoposide. Two stepwise doublings of the drug concentration were needed before PC4 cells acquired vincristine resistance, but there was no detectable overexpression of mdr or a change in anthracycline uptake. In a subsequent doubling of Adriamycin concentration, the cells showed a further increase in resistance to all three drugs and now a decreased anthracycline accumulation. However, there was still no detectable increase in mdr expression as judged by Northern analysis of poly(A)+ enriched RNA and Western blot analysis of membrane proteins. Only after a fourth doubling of Adriamycin concentration did the cells demonstrate enhanced expression of mdr and P-glycoprotein. Equivalent mutants of C7D were selected, but generally at lower Adriamycin concentrations. Verapamil partially lowered resistance, but failed to restore parental susceptibility in any mutant; it caused an increased uptake in those mutants showing decreased anthracycline accumulation, including those that did not overexpress mdr. This study demonstrated different resistance phenotypes among mutants appearing spontaneously under stepwise drug selection; mutants with vincristine resistance and decreased anthracycline uptake preceded those associated with over-expression of P-glycoprotein.
从小鼠红白血病细胞系PC4中分离出第一步对阿霉素(多柔比星)耐药的突变体,这些突变体是从含有阿霉素(10 ng/ml)的甲基纤维素中克隆得到的,克隆频率为3×10⁻⁴。它们对阿霉素表现出1.6至2.4倍的稳定耐药性。大多数突变体对依托泊苷交叉耐药,但对长春新碱不耐药,且mdr基因(编码P-糖蛋白)无增强表达。将两种不同的小鼠红白血病细胞系PC4和C7D在悬浮培养中传代至逐步增加剂量的阿霉素中。未重新分离出高水平耐药突变体;细胞最初对阿霉素和依托泊苷表现出低水平耐药。PC4细胞在获得长春新碱耐药性之前需要将药物浓度进行两次逐步加倍,但未检测到mdr的过表达或蒽环类药物摄取的变化。在随后将阿霉素浓度加倍时,细胞对所有三种药物的耐药性进一步增加,此时蒽环类药物积累减少。然而,通过对富含聚腺苷酸的RNA进行Northern分析以及对膜蛋白进行Western印迹分析判断,mdr表达仍未检测到增加。仅在将阿霉素浓度第四次加倍后,细胞才表现出mdr和P-糖蛋白的增强表达。选择了C7D的等效突变体,但通常是在较低的阿霉素浓度下。维拉帕米部分降低了耐药性,但未能恢复任何突变体的亲本敏感性;它使那些蒽环类药物积累减少的突变体(包括那些未过表达mdr的突变体)的摄取增加。本研究证明了在逐步药物选择下自发出现的突变体之间存在不同的耐药表型;具有长春新碱耐药性和蒽环类药物摄取减少的突变体先于与P-糖蛋白过表达相关的突变体出现。